NUTRITION 21 Bioaktie?

.M. Dutton & Associates Announces Investment Opinion: Nutrition 21, Inc. Buy Rating Maintained in Update Coverage by Dutton & Associates
Tuesday January 11, 2:30 pm ET

EL DORADO HILLS, Calif.--(BUSINESS WIRE)--Jan. 11, 2005--J.M. Dutton & Associates updates its coverage of Nutrition 21, Inc. (Nasdaq:NXXI - News), maintaining a Buy rating and a $1.70 price target. The 9-page report by J.M. Dutton senior analyst William R. Prather R.Ph., M.D., is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, and other leading financial portals. Nutrition 21 has been a supplier of chromium picolinate to the nutritional market since 1998. New management is successfully executing the strategy of elevating their product from a food supplement to a medical ingredient.

About Dutton & Associates

Dutton & Associates is one of the largest independent investment research firms in the U.S. Its 25 senior analysts are primarily CFAs, and have expertise in many industries. Dutton & Associates provides continuing analyst coverage of over 70 enrolled companies, and its research, estimates, and ratings are carried in all the major databases serving institutions and online investors.

The cost of enrollment in our one-year continuing research program is US $33,000 prepaid before commencement of our research activities. We received $28,000 from the Company for 4 Research Reports with coverage commencing on 7/6/2004. Our principals and analysts are prohibited from owning or trading in securities of covered companies. The views expressed in this research report accurately reflect the analyst's personal views about the subject securities or issuer. Neither the analyst's compensation nor the compensation received by us is in any way related to the specific ratings or views contained in this research report or note. Please read full disclosures and analyst background at www.jmdutton.com before investing.  

, denn ich kann mir nicht vorstellen, dass die FDA gänzlich anders als die FSA entscheidet. Vielleicht von der ganzen Latte an Bestätigungen gegen die Chromax alles wirkt (sind glaube ich um die 10), dass vielleicht die FDA ein paar nicht bestätigt, aber ich denke den Grossteil schon und dann kann NXXI auch groß die Werbetrommel rühren und die Verkäufe werden explodieren...

Gruß S1  

January 11, 2005. Nutrition 21, Inc. (Nasdaq: NXXI) has been a supplier of chromium picolinate to the nutritional market since 1998. New management is successfully executing the strategy of elevating their product from a food supplement to a medical ingredient. When we initiated coverage of Nutrition 21 in July 2004 we emphasized the importance of the Company’s pending application to the FDA for health claims associating chromium picolinate with a reduced risk of insulin resistance in type 2 diabetes and related disease conditions. The FDA was to complete its review of the application by November 18, 2004 but has subsequently requested a 90-day extension because of a lack of resources needed to complete the review. Nutrition 21 accepted this extension on December 2, 2004, which places the new deadline for the FDA at February 16, 2004. The Company also plans to file for similar approvals in the EU and Canada. We believe the FDA may need an additional two to three months after this February deadline to process the application. However, we are confident it will allow some form and substance of a health claim that Nutrition 21 will be able to use to their benefit in marketing Chromax(R), their form of chromium picolinate, and Diachrome(TM), a combination of Chromax and biotin. We are maintaining our Buy rating and our 12-month price target of $1.70.
 

Aus der obigen Mitteilung geht hervor, dass der Analyst einschätzt, die FDA könne durchaus 2-3 Monate über den Stichtag 16.Febrau hinaus benötigen. Er ist aber zuversichtlich für die Zustimmung. Das 12-Monatsziel 1,70 $ wurde im Juli 04 erstellt und nun bestätigt. D.h. das ist das Ziel bis Juli. Nach dem FDA-Approval wird es dann –so oder so- eine Neubewertung geben. Somit wäre es sinnvoll länger drin zu bleiben weil gerade der September anscheinend ein guter Monat für den NXXI-Kurs ist.  

Hoffen wir mal Mannemer, dass Sie die Zeit nicht benötigen. Mittlerweile kann mich was den Zeitpunkt betrifft schon nichts mehr wirklich erschüttern, aber meine positive Meinung bleibt bestehen ;-)

Gruß S1  

Meine positive Meinung bleibt auch bestehen. Je mehr ich mich damit befasse, je mehr bin ich überzeugt hier ein gutes Geschäft machen zu können. Ich habe daher nochmal geordert. Der jetztige Zeitpunkt erscheint günstig.

Nur einige Monate Geduld werden wir brauchen. Die 1,70 $ sehe ich im Sommer. Im Herbst könnte es dann im wahrsten Sinne einen "Goldenen Oktober" geben.    

es ist aber bisher bei nxxi sehr hilfreich gewesen!

Im Moment sollte laut FDA bis längstens 16.Februar 2005 die Entscheidung fallen!

Die "2-3 Montate nochmalige Verlängerung" sind nur die Vermutung von einem Analysten:

...We believe the FDA may need an additional two to three months after this February deadline to process the application. However, we are confident it will allow some form and substance of a health claim that Nutrition 21 will be able to use to their benefit in marketing Chromax(R), their form of chromium picolinate, and Diachrome(TM), a combination of Chromax and biotin. We are maintaining our Buy rating and our 12-month price target of $1.70.

Gruß S1  

Neue Studien! Siehe ganz unten!

PURCHASE, N.Y.--(BUSINESS WIRE)--Dec. 16, 2004-- Nutrition 21, Inc. (Nasdaq: NXXI - News) announced today that a bill signed into law by President George Bush includes Report Language that recognizes that "chromium picolinate can restore normal glucose metabolism by enhancing insulin sensitivity," and encourages the National Center for Complementary and Alternative Medicine (NCCAM) to expand its chromium research program. The bill supports earlier findings for chromium supplementation in delaying the onset of diabetes in certain high-risk populations including Native American and pediatric populations.
The language is part of the Fiscal 2005, Labor-Health Subcommittee on Appropriations bill that provides for an $800 million increase in the National Institutes of Health (NIH) budget over last year as part of Congress' continued commitment to curing disease through NIH research.

"Given the chronic nature and the devastating economic impact of type 2 diabetes, it is important to use the most cost-effective measures to help improve glycemic control in people living with the disease," said Gail Montgomery, president and CEO of Nutrition 21. "This government recognition of chromium picolinate research and preliminary pharmacoeconomic analysis indicating healthcare savings is another important milestone in our effort to raise public awareness and to increase visibility within the medical and academic research communities of the benefits of chromium picolinate supplementation."

Chromium is an essential mineral that is critical to proper insulin function. Low chromium levels have been linked with increased risk of insulin-based diseases, such as type 2 diabetes, obesity and heart disease. Chromium picolinate is increasingly recognized among health professionals and consumers for its role as a safe and effective nutritional supplement for people with insulin resistance and at risk for diabetes -- a worldwide epidemic affecting an estimated 190 million people.

To date, there are three NIH funded ongoing clinical trial programs studying chromium picolinate's role in diabetic and pre-diabetic populations, and a fourth has been approved. In addition, the relationship between chromium and weight gain is being evaluated in the Look AHEAD Study by John Hopkins researchers.

Gruß S1  

... und keiner weiß was los ist. Der offiziele Börsenschluss lag bei 0,87 ; außerbörslich stieg er dann auf 0,96. Weiß jemand dazu Hintergründe ?  

es kann jeden Tag sein, dass die FDA mit Ihrer Meldung kommt! Laut FDA wollen Sie das bis 16.02.2005 schaffen, solange läuft die tatsächliche 90 Tage Verlängerungsfrist.

Hab mir den Intradaychart von gestern angesehen. Der Kurs ging nicht über 0,9$ und das bei nur 130.000 gehandelten Stück! Kannst Du mir das nachbörsliche gehandelte Volumen verraten Mannemer?

Das wäre ein weiterer Indikator...

Geduldige Grüße S1  

...das Volumen kann ich nicht erkennen. Die außerbörslichen Kurse sind im Moment über US-Yahoo nicht mehr abrufbar. Im US-Yahoo-Forum fragen sich auch einige nach den Hintergründen. In Deutschland ist keine außergewöhnliche Bewegung erkennbar. Möglicherweise ist auch jemand unvorsichtig mit einem unlimitierten Kaufauftrag reingegangen und schaut jetzt blöde. Warten wir noch ein paar Stunden, dann sehen wir ob sich bereits im Januar was entwickelt. Im Vorfeld einer FDA-Veröffentlichung könnten Insider-Käufe beginnen. Das ist aber alles ungewiß. Kann auch erst sein 16.2. + 3 Monate.  

Y! nachgelesen Mannemer und dabei diesen interessanten Link gefunden:

http://www.stockpickreport.com/abrating.php?sym=nxxi

Bin sehr zuversichtlich, wäre schön, wenn es sich nur um Stunden handeln würde, wenn nicht, dann sind es eben Tage oder mehr...

Gruß S1  

...gegen 16.00 Uhr wissen wir mehr. Selbst wenn sich was täte bezüglich FDA, die wirklich interessanten Kurse kommen dann erst in einigen Monaten. Wenn kompetente und finanzkräftige Partner für die Vermarktung mit ins Boot kommen, dann sind die für 2007 großspurig verkündeten 8 Dollar vielleicht wirklich realistisch, u.U. schon in den nächsten 12 Monaten. Historisch hat die Aktie ja bereits an diesem Niveau gekratzt.  

 

...irgendeiner ist wahrscheinlich ohne Limit rein und prompt auf die Nase gefallen. Ich schätze erst der Februar wird so richtig interessant.  

 

http://www.americanbulls.com/...nyTicker=NXXI&MarketTicker=NASD&TYP=S  

Americanbulls hat wie Kicky gelinkt hat von Sell auf Hold upgegradet.  

Das Ding zischt ab wie eine Rakete. Seit Börseneröffnung in NY schon ein Plus von fast 19 % bei hohem Volumen. Der Tag wird interessant. Vermute es gibt Neuigkeiten.  

Tuesday January 25, 9:33 am ET

Nutrition 21 and XL Health Report Positive Results for Diachrome Clinical Trial in People with Type 2 Diabetes

Commercialization Plans of Nutrition 21 on Track for Nutritional Therapy for Diabetes and Heart Disease

PURCHASE, N.Y. & BALTIMORE--(BUSINESS WIRE)--Jan. 25, 2005-- Nutrition 21, Inc. (NXXI: NASDAQ) and XL Health Corporation announced today positive results from a pivotal randomized, double-blinded, placebo-controlled clinical trial evaluating the effects of Diachrome®, a combination of chromium picolinate and biotin, on glycated hemoglobin (HbA1c), fasting plasma glucose, cholesterol and triglyceride profiles in patients with type 2 diabetes. The 453 patient multi-center trial was conducted by Nutrition 21 in collaboration with XL Health, a nationally recognized disease management firm managing chronically ill patients for the Centers for Medicare and Medicaid Services (CMS) and private Medicare Advantage markets. It is the largest U.S. study to demonstrate the health benefits of a chromium-based intervention for diabetes.
"The detailed findings from the trial are being shared with a number of clinical outcomes groups at both XL Health and Nutrition 21," said Paul Serini, executive vice president of XL Health. "Based on the positive trial results we have seen thus far and the apparent benefits to our diabetic patients' health and medical spending, XL Health is investigating ways the Diachrome product can be incorporated on a broad scale into the work we do with CMS and Medicare Advantage patients."
"This major clinical milestone for Diachrome further confirms its safety and benefits in uniquely managing both blood sugar and cholesterol levels in conjunction with pharmaceutical treatments for people with diabetes," commented Gail Montgomery, president and CEO of Nutrition 21. "We are currently sharing the data with strategic business partners and key medical experts to enlist their support in accelerating our efforts to move Diachrome into clinical practice as a nutritional therapy for people with diabetes and at risk for heart disease."
According to the American Diabetes Association, there are 18.2 million people in the United States, or 6.3% of the population, who have diabetes. Heart disease is the leading cause of diabetes-related deaths and adults with diabetes have heart disease death rates about 2 to 4 times higher than adults without diabetes. The cost of diabetes, both direct medical expenditures and the costs of foregone productivity, is estimated to have been $132 billion in 2002.
"Given the increasing public health burden associated with the escalating incidence of diabetes, we believe the market potential for Diachrome, as a safe, effective and inexpensive adjunct therapy to diabetes disease management is significant. We eagerly await the opportunity to present the data at key scientific meetings in the months ahead," added Montgomery.
About Nutrition 21
Nutrition 21 is a nutritional bioscience company and the maker of chromium-based supplements with health benefits substantiated by clinical research. The company markets Chromax® chromium picolinate, which is the most-studied form of the essential mineral chromium. Nutrition 21 also developed Diachrome®, which is available through diabetes educators or at www.diachrome.com. Nutrition 21 holds 36 patents for nutrition products and uses, 27 of which are for chromium compounds and their uses. More information is available at www.nutrition21.com.
About XLHealth Corporation
XLHealth (www.xlhealth.com) is a privately held company owned by a combination of founders, management and Goldman Sachs Private Equity Funds. It has been at the forefront of disease management innovations since its inception. Founded by physicians, many of whom were affiliated with Johns Hopkins, XLHealth replaces the more customary remote telephone "call-center" or direct mail support with ongoing, face-to-face meetings with patients and physicians. XLHealth also uses tight coordination of care, behavior modification, and in-depth patient profiling integrated with claims, pharmacy, and lab information to generate sophisticated, predictive modeling. The firm emphasizes preventing avoidable and expensive disease complications and hospitalizations. XLHealth was recently awarded the Disease Management Association of America's (DMAA) Recognizing Excellence Award for "Best Disease Management Program: Medicare."
The statements contained in this release which are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company's control with respect to market acceptance of new technologies and products, delays in testing and evaluation of products, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.


 

 

...im Moment sind es "nur noch" + 13 %. Wenn sich die Aktie bis zum FDA-Entscheid, der möglicherweise bis 16.Februar erfolgt, weiter vor arbeitet, könnte es bei einem positiven Entscheid zu einer ganz schönen Ralley kommen.  

Habe letzten Tage Eure news über nutrition 21 gelesen , und
heute mal 5000 Stück gekauft , hoffe es war kein Fehler und
sie steigen auch noch in den nächsten Tagen und fallen nicht gleich
wieder in den Keller , danke wenn ihr wieder neue
Nachrichten einstellt .
auf hohe Kurse
hoelli7  

Willkommen im Club!
Ich glaube hier lohnt es sich etwas Geduld zu haben. Nicht nur auf die nächsten Tage sehen! Die Aktie wird bestimmt noch manche Zick-Zack-Bewegung vollziehen. Ich kann mir aber vorstellen, dass auf Sicht von 12 Monaten hier so richtig Geld zu verdienen ist. Das könnte durchaus auf eine Vervierfachung ( 3,50 - 4 Dollar) hinauslaufen. Der Knackpunkt wird die Beurteilung der FDA sein. Die heutige Studie könnte den Optimismus anheizen.  

...da hat irgendwann in NY einige der Mut verlassen. Trotzdem, 11 % heute ist gut. Wichtig auch: Die Grenze bei 1 Dollar wurde wieder geknackt. Durch die Studie kommt wieder Fantasie in das Papier. Alles starrt jetzt auf die FDA. Bin mal gespannt auf den morgigen Tag in NY.